Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    NEXT STORY
    Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
    PREV STORY
    Digital Radiography Market to Reach US$ 2,978.3 Mn by 2026, FDA Clearance to Philips and Other Companies to Enable Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ALRT Introduces Value Pricing for Diabetes Management

    RICHMOND, Va., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Medical practices, health insurers, self-insured employers, ...

    author_avatar
    NASDAQ Market News

    Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

    SAN RAMON, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a ...

    author_avatar
    NASDAQ Market News

    Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study

    SOUTH SAN FRANCISCO, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), ...

    author_avatar
    NASDAQ Market News